

Evonik opens a new facility for its Health Care business in Darmstadt

At the beginning of 2014 Evonik will open a new facility in Darmstadt to host the manufacturing and development of RESOMER® products as well as some formulation development activities for customers' drug products. The 4,000 m² production and laboratory facility constructed over the last 18 months will start welcoming personnel and equipment as early as January and will open officially in the second quarter of 2014.

The RESOMER® business was acquired from Boehringer Ingelheim in March 2011. It was then agreed that production and development could remain at the Ingelheim campus of Boehringer Ingelheim for a period of 36 months to assure business continuity.

“The transfer of the RESOMER® production from Ingelheim to Darmstadt is on schedule,” says Dr. Jean-Luc Herbeaux, Head of the Health Care Business Line of Evonik. “We look forward to having our teams together at our Darmstadt campus as the final step in the integration of the RESOMER® business.”

The new building was designed specifically for RESOMER® production: “All production steps will be carried out in a closed clean-room environment in one building” explains Dr. Jörg Pietsch, Head of RESOMER® production.

The RESOMER® business comprises a portfolio of standard and customized polymers used in the manufacture of medical devices and pharmaceutical formulations. Based on lactic and glycolic acids, RESOMER® polymers are fully biodegradable in the body. Biodegradable polymers are used for controlled release depot formulations (such as gel, microspheres and rod implants) with a therapeutic effect for up to six months. The lactic acid polymers are also used in the manufacture of biodegradable medical devices such as surgical screws, nails, and plates which disintegrate

January 30, 2014

Contact person specialized press
Dr. Jürgen Krauter
Communication Health & Nutrition
Tel. +49 (0)6181 59-6847
Fax +49 (0)6181 59-76847
juergen.krauter@evonik.com

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Telefax +49 201 177-3475
www.evonik.de

Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Thomas Wessel
Patrik Wohlhauser
Ute Wolf

Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003

without trace after a defined life span in the body, making further surgery to extract them unnecessary.

RESOMER® is part of the Evonik's Health Care portfolio of differentiated products and services for the pharmaceutical and medical device industry. From drug substance custom manufacturing to excipients for oral (EUDRAGIT®) and parenteral (RESOMER®) formulations, from formulation development to clinical and commercial drug product supply, Evonik covers the entire drug development value chain. The ability to access a broad range of competencies and differentiated technologies makes Evonik the enabling partner to the pharmaceutical and medical device industry.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.